Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  237.91
-6.28 (-2.57%)
AAPL  272.79
-0.68 (-0.25%)
AMD  247.66
-11.22 (-4.34%)
BAC  53.20
-0.91 (-1.67%)
GOOG  279.65
-7.78 (-2.71%)
META  606.28
-2.73 (-0.45%)
MSFT  503.10
-8.04 (-1.57%)
NVDA  185.62
-8.18 (-4.22%)
ORCL  216.35
-10.64 (-4.69%)
TSLA  399.44
-31.16 (-7.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.